Technology Matters: How the Pap Test Protects Your Patients


The Pap test reduces the incidence of cervical cancer and its precursors for women around the world but has limitations in sensitivity and accuracy.

Liquid-based cytology improves detection of dysplasia and cervical malignancy while producing fewer unsatisfactory or insufficient results. This supplement examines the science, development and clinical benefits of ThinPrep® - the first FDA-approved, liquid-based cytological testing method for women aged 30 and older.

Read this online supplement to learn more about the latest in developments in cervical cancer screening.

Download Supplement



Related Videos
The significance of the Supreme Court upholding mifepristone access | Image Credit:
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit:
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit:
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit:
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit:
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit:
raanan meyer, md
Related Content
© 2024 MJH Life Sciences

All rights reserved.